Review

Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review

Daniele Focosi 1,*, Fabrizio Maggi 2,3,*, Massimo Franchini 4,*, Scott McConnell 5,6 and Arturo Casadevall 5,6

1 North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy
2 Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy; fabrizio.maggi63@gmail.com
3 Laboratory of Microbiology, Azienda Socio Sanitaria Territoriale Sette Laghi, 21100 Varese, Italy
4 Division of Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy; massimo.franchini@asst-mantova.it
5 Department of Medicine, Johns Hopkins School of Public Health, Baltimore, MD 21218, USA; smcconn8@jhu.edu (S.M.);acasade1@jhu.edu (A.C.)
6 Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21218, USA
* Correspondence: daniele.focosi@gmail.com

Abstract: The accelerated SARS-CoV-2 evolution under selective pressure by massive deployment of neutralizing antibody-based therapeutics is a concern with potentially severe implications for public health. We review here reports of documented immune escape after treatment with monoclonal antibodies and COVID-19-convalescent plasma (CCP). While the former is mainly associated with specific single amino acid mutations at residues within the receptor-binding domain (e.g., E484K/Q, Q493R, and S494P), a few cases of immune evasion after CCP were associated with recurrent deletions within the N-terminal domain of the spike protein (e.g., ΔHV69-70, ΔLGVY141-144 and ΔAL243-244). The continuous genomic monitoring of non-responders is needed to better understand immune escape frequencies and the fitness of emerging variants.

Keywords: SARS-CoV-2; COVID-19; convalescent plasma; viral clearance

1. Introduction

The SARS-CoV-2 spike protein is the target of neutralizing antibody (nAb)-based therapeutics. Control of the COVID-19 pandemic is being hampered by continued evolution of SARS-CoV-2, which includes mutations in the spike protein that can affect immunogenicity and antibody-mediated neutralization. Evolutionary modeling suggests that SARS-CoV-2 strains harboring 1–2 deleterious mutations naturally exist, and their frequency increases steeply under positive selection by monoclonal antibodies (mAb) and vaccines [1]. In 2% of COVID cases, SARS-CoV-2 variants with multiple mutations occur, including in the spike glycoprotein, which can become the dominant strains in as little as one month of persistent in-patient virus replication [2]. While mutations can occur as a natural phenomenon of SARS-CoV-2 RNA replication and editing, the pace of mutagen emergence can also be affected by small-chemical antivirals (e.g., remdesivir [3] or molnupiravir [4]). Since antibody-based therapies targeting the spike protein would also put selective pressure on SARS-CoV-2, it is reasonable to assume that widespread deployment of nAb-based therapeutics could accelerate spike immune escape by selecting for variants that resist neutralization.

Mutations that confer in vitro resistance to therapeutic anti-spike mAbs have been characterized with various methods and are informative about treatment-emergent immune escape. Deep mutational scanning (DMS) predicts protein expression, ACE2 binding, and mAb binding [5]. The method was first deployed with yeast display libraries [6], then evolved to phage display libraries (https://jbloomlab.github.io/SARS-CoV-2-RBD_MAP_clinical_Abs/) [7] and finally mammalian cell surface display [8]. mAb binding is common within the fusion peptide and in the linker region before heptad repeat (HR) region 2.
The complete escape maps forecast SARS-CoV-2 mutants emerging during treatment with mAbs and allow the design of escape-resistant nAb cocktails. A complete map of SARS-CoV-2 RBD mutations that escape bamlanivimab and its cocktail with etesevimab has been generated [9,10].

Although DMS was also applied to polyclonal antibodies in COVID-19-convalescent plasma (CCP) [11], the problem is much more complex, such that it is almost impossible to identify escape mutations in CCP or vaccinee-elicited sera, given the huge heterogeneity in antibody response among CCP donors and vaccinees, respectively. In vitro, continuous passaging of SARS-CoV-2 in the presence of a CCP unit with nAb titer >1:10^4 led to ΔF140 spike mutation at day 45, followed by E484K at day 73, and an insertion in the N-terminal domain (NTD): these accumulating mutations led to complete immune escape [12]. Similarly, K417N, E484K, and N501Y mutations were selected when pseudotyped SARS-CoV-2 was cultured in the presence of vaccine-elicited mAbs [13]. Although some have speculated that the large-scale use of CCP for COVID-19 could have played a role in the emergence of variants, there is no evidence for such an effect and the most likely explanation for the regular emergence of variants has been the huge number of affected individuals since each infection case provides a natural opportunity for variant creation [14].

In vivo, while intrahost-SARS-CoV-2 mutation development is typically very low [15], faster mutation rates (referred to as “accelerated evolution”) have been found in longitudinal studies of immunodeficient patients who had persistent SARS-CoV-2 infections for several months and were treated with nAb-based therapeutics. In this study, we analyze and compare the available mutational data from SARS-CoV-2 under in vitro and in vivo selection and demonstrate that mAb and polyclonal (CCP) therapies elicit different types of mutational patterns.

2. Materials and Methods

We mined PubMed (which also indexes the bioRxiv and medRxiv preprint servers) for keywords related to COVID-19 (“COVID-19”, “SARS-CoV-2”), immune escape (“immune escape”, “treatment-emergent resistance”) and nAb-based therapeutics (“convalescent plasma”, “casirivimab”, “imdevimab”, “bamlanivimab”, “etesevimab”, “regdanvimab”) both in vitro and in vivo. Clinical cases were annotated for eventual underlying immune deficiency, concurrent treatments and outcome. Figure 1 reports the study selection process according to PRISMA 2020 guidelines [16].

The 3D structural coordinates of the full spike protein (PDBID 6VXX; residues 27–1252) [16] and the receptor binding domain (PDBID 7BWJ; residues 319–529) [17], solved by cryo-electron microscopy and X-ray crystallography, respectively, were used to map mutational positions of interest. Mapping on the full spike was used to illustrate the diverse set of mutations throughout the spike glycoprotein, while the mutations localized to the RBD were illustrated using the more complete structural model obtained through crystallography. The mutations identified in each condition of in vivo or in vitro selection were tabulated and highlighted on the structures using color coding with PyMOL v.2.4.1. (Schrodinger, Mannheim, Germany) [18].
3. Results

Our literature search revealed 32 papers that were then manually inspected to determine whether they included relevant information that was then retrieved, evaluated and organized into Tables.

Table 1 summarizes spike protein mutations associated with in vitro resistance to mAbs targeting this protein. These mutations were used to filter the clinical case reports of treatment resistance for evidence of immune escape (Table 2).
**Table 1.** Spike mutations associated with clinically-approved mAb resistance in vitro, sourced via the Stanford University Coronavirus Antiviral and Resistance Database (accessed online on 13 December 2021, at https://covdb.stanford.edu/search-drdb/). Mutations conferring resistance to both mAbs within the cocktail are underlined.

| Manufacturer | Cocktail Brand Name | Active Ingredient (Brand Name) | Spike Mutations Associated with In Vitro Resistance | Ref |
|--------------|---------------------|---------------------------------|-----------------------------------------------------|-----|
| Eli Lilly (AbCellera/Junshi) | n.a. | etesevimab (LyCoV016, CB6, JS016, LY3832479) | K417N/T (100 folds), D420N (100 folds) E456R/A/K (100 folds) N460K/S/T/Y (50–100 folds) I472D A475R/V (20–100 folds) E484K N487R (100 folds) G485P Q493R/K (100 folds) | [9,10,19] |
| | | bamlanivimab (LY-CoV555, LY3819253) | L452R (>100 folds) E484D/K/Q (>100 folds) G485P F490S/L (100 folds) Q493R/K (100 folds) S494P/R (100 folds) | |
| Regeneron/Roche | REGN-COV2 (Ronapreve) | imdevimab (REGN10987) | E406W (>100 folds) N439K (25–100 folds) N440K (28–96 folds) K444L/M/N/Q/T (>100 folds) V445A (>100 folds) G446V (>100 folds) N450D (9–32 folds) Q498H (17 folds) P499S (>100 folds) E484K (16 folds) | [9] |
| | | casirivimab (REGN10933) | E406W/D (50–93 folds) K417E/N/R/T (25–100 folds) V455T (>100 folds) Y455F (>100 folds) L455F (80 folds) A475R (44 folds) E484K/Q (20–55 folds) F486x F486K/L/R/S/V (>100 folds) N487R (>100 folds) Q493E/K/R (25–100 folds) | |
| AstraZeneca | AZD7442 long-acting antibody (LAAB)(Evusheld) | tixagevimab (AZD8895/COV2-2196) | E484K (4–11 folds) S982A (3.2 folds) | [13,20–22] |
| | | cilgavimab (AZD1061/COV2-2130) | | |
| Celltrion | - | regdanvimab (CT-P59) (Regkirona) | L452R (35 folds) E484K (8.7 folds) N501Y (5.5 folds) | [23] |
| GSK | - | sotrovimab (VIR-7831, S309, GSK4182136) (Xevudy) | P337R/L/H/T (180–276 folds) E340K/A/G (27–300 folds) | [24,25] |
### Table 2. Case reports of immune escape after anti-spike mAb treatment.

| mAb Type | Age/Sex (Identifier) | Condition (Treatments) | Day mAb Administered | Other Antiviral Treatments | SARS-CoV-2 Strain | Spike Mutations | First Detected at Day | Outcome | Ref |
|----------|----------------------|------------------------|-----------------------|---------------------------|-------------------|-----------------|---------------------|---------|-----|
| REGN-CoV2 cocktail | 45/M | antiphospholipid syndrome (steroids, rituximab, rituximab, cyclophosphamide) | 45 | remdesivir (5 + 10 + 5 days) | n.a. | E484K/A, Y489H, Q493R and N501Y | 75 | death | Choi et al. [20] Clarke et al. [21] |
| n.a./n.a. (B2_11) | n.a. | n.a. | E484K | 3 after mAb | n.a. | n.a. | Alpha E484Q 22 discharged day 43 | recovered, negative at day 91 | Lohr et al. [24] |
| n.a./n.a. (B2_8) | n.a. | n.a. | E484K | 2 after mAb | n.a. | n.a. | discharged at day 91 | recovered, negative at day 91 | Jensen et al. [25] |
| n.a./n.a. (B2_6) | n.a. | n.a. | E484K | 6 after mAb | n.a. | n.a. | Alpha E484K and Q493R 6 recovered at day 61 | recovered at day 61 | Truffot et al. [23] |
| Bamlanivimab monotherapy (700 mg iv) | 72/M | chronic lymphocytic leukemia and hypogammaglobulinemia (rituximab and prednisolone) | 4 (700 mg) | 1 BNT162b2 dose 20 days before CPP day 10 | Alpha E484K and Q493R | 6 | negative at day 51 | discharged at day 40 after 2 negative NPS | Truffot et al. [23] |
| 55/F | acute myeloid leukemia | 14 | Remdesivir days 23–27 | B.1 | E484K revert to E484K after CPP | 12 | died of MOF on day 20 | died of MOF on day 20 | Lohr et al. [24] |
| 70/M | ANCA-associated vasculitis with end-stage renal disease (rituximab and prednisolone) | 2 | 3 units of CCP at day 16 | B.1 | E484K | 21 | negative at day 51 | discharged at day 40 after 2 negative NPS | Lohr et al. [24] |
| 40/F | AIDS | 3 | remdesivir and 2 units of CCP | B.1. | E484K | 10 | recovered | recovered at day 103 | Jensen et al. [25] |
| 60/M | relapsed follicular lymphoma (obinutuzumab, thiotepa, cytarabine, etoposide) | 76 | 2 CCP units on day 57 and 1 CCP unit on day 59 | B.1.177 | E484K | 87 | recovered, negative at day 103 | discharged at day 40 after 2 negative NPS | Lohr et al. [24] |
| 65/M | heart transplant recipient (about 30 years ago) (cyclosporine, azathioprine, prednisolone) | 2 | none | B.1.177 | E484K | 19 | discharged at day 91 | discharged at day 91 | Lohr et al. [24] |
| 65/M | chronic lymphatic leukemia | 45 | remdesivir and 3 units of CCP days 52-62, imdevimab/casirivimab about day 70 | B.1.258 | E484K | 52 | recovered, negative at day 91 | discharged at day 43 | Lohr et al. [24] |
| 33/M | Hodgkin lymphoma (untreated) | 20 | dexamethasone | B.1.362 | APL10 → APFLGVY139-144, G485R, W258C | 45 | hospitalized for HL chemotherapy at end of follow-up | hospitalized for HL chemotherapy at end of follow-up | Bronstein et al. [26] |
| 68/M | chronic lymphocytic leukemia (FLR in 2017, prednisone for AIHA, prednisone for AIHA, venetoclax + rituximab in 2019) | 10 | CPP days 12 and 26, IVIg, day 21, remdesivir days 37-41 | Alpha | E484Q | 22 | discharged day 43 | discharged day 43 | Sabin et al. [27] |
| n.a. | immunocompetent | 2 | n.a. | B.1.311 | E484K | n.a. | resolved at home | discharged at day 27 | Heinrich et al. [28] |
| 87/M | immunocompetent | 2 | none | Alpha | E484K | 6 | discharged negative at day 27 | discharged, negative at day 38 | Peiffer-Smadelja et al. [29] |
| 35/M | immunocompetent | 2 | none | Alpha | E484A/K | 6 | discharged, negative at day 38 | discharged, negative at day 38 | Peiffer-Smadelja et al. [29] |
Table 2. Cont.

| mAb Type | Age/Sex (Identifier) | Condition (Treatments) | Day mAb Administered | Other Antiviral Treatments | SARS-CoV-2 Strain | Spike Mutations | First Detected at Day | Outcome | Ref |
|----------|----------------------|------------------------|----------------------|---------------------------|-----------------|----------------|-----------------------|---------|-----|
| 61/M     | immunocompetent      | 2 steroids             | steroids             | Alpha E484K               |                 | 12             | negative               | day 8    |     |
|          |                      |                        |                      |                           |                 |                | hospitalized           | for unrelated reasons |     |
| 97/M     | immunocompetent      | 4 none                 | none                 | Alpha E484K               |                 | 14             | died                  | day 35   |     |
|          |                      |                        |                      |                           |                 |                | because of soft tissue infection |         |     |
| 64/M     | heart transplant recipient | 2 corticosteroids for 10 days | Alpha Q493R         | 26                         | discharged, negative at day 48 |     |
|          |                      |                        |                      |                           |                 |                |                       |         |     |

| n.a.     | n.a.                 | 2                      | n.a.                 | S494P                     | 11              | recovered, not detected in samples at day |         |     |
| 73/M     | cholangiocarcinoma   | 2                      | none                 | Alpha Q493R               | 7               | died day 18 |                       |         |     |
|          | (steroids)           |                        |                      |                           |                 |                |                       |         |     |
| 63/M     | allogeneic hematopoietic stem cell transplantation recipient for mycosis fungoides | n.a. | none | Alpha Q493R | 15 | discharged at day 2 |                       |         |     |
| 63/M     | solid organ transplantation | n.a. | none | Alpha Q493R | 7 | n.a |                       |         |     |
|          |                      |                        |                      |                           |                 |                |                       |         |     |
| 67/F     | follicular lymphoma  |                       <5 days      |                      | n.a.                      | E484K           | 21             | n.a                   |         |     |
|          |                      |                        |                      |                           |                 |                |                       |         |     |
| 34/F     | B-ALL                | 2 CCP units days 29–30 | Alpha Q493R          | n.a.                      |                 |               |                       |         |     |
|          |                      |                        |                      |                           |                 |                |                       |         |     |
| 62/F     | Hodgkin lymphoma     | 1 CCP unit day 28      | Alpha Q493R          | n.a.                      |                 |               |                       |         |     |
| 63/F     | follicular lymphoma  | 2 CCP units days 30–31 | Alpha Q493R          | n.a.                      |                 |               |                       |         |     |
| 67/F     | follicular lymphoma  | 2 CCP units days 15–16 | Alpha Q493R          | n.a.                      |                 |               |                       |         |     |
| 34/F     | follicular lymphoma  | 2 CCP units days 30–31 | Alpha Q493R          | n.a.                      |                 |               |                       |         |     |
|          |                      |                        |                      |                           |                 |                |                       |         |     |

Table 3 summarizes the spike mutations found in clinical cases after CCP treatment, where immune escape can be hypothesized to have occurred based on treatment failure, with the caveat that there is no definitive proof of immune escape due to heterogeneity of the (uncharacterized) polyclonal response.

Table 3. Case reports of immune escape after CCP treatment.

| Age/Sex (Identifier) | Condition | CCP Schedule (and Titer) | Co-Treatments | SARS-CoV-2 Strain | Spike Mutations | First Detected at Day | Outcome | Ref |
|----------------------|-----------|--------------------------|---------------|-----------------|----------------|-----------------------|---------|-----|
| 71/F                 | chronic lymphocytic leukemia and iatrogenic hypogammaglobulinemia | 70 (1:40) and 81 (1:160) | IVIG q4-6w | n.a. | APFLGVYY139–145 | 49 | negative | day 105 | Avanzato et al. [34] |
| 73/M                 | chimeric antigen receptor T-cell recipient | low titer days 2 and 58 | remdesivir days 5–10, 63–74 desamethasone days | GH | R190K and G1124D | 13 | died | day 74 | Hensley et al. [35] |
| 70/M                 | B-cell depletion and hypogammaglobulinemia | 63, 65, 102 | remdesivir day 38–48, 52–62 and 91–101 | n.a. | D96H and ΔHV69–70 | 57 | died | day 102 | Kemp et al. [36] |
| 21/M                 | B-acute lymphoblastic leukemia (tisagenlecleucel) | 79, 119, 57, 130, 137, 144, 158, 165, 172 | remdesivir (2 × 5-day courses) | n.a. | 3 major allele variants emerged between days 0 and 40 with an additional 4 major and 7 minor allele variants by day 144 (ΔLGV141–144, ΔY415, ΔLGVY141–144, ΔNL211–212, N440K, V483A, and E484Q) | 144 | positive NPS at end of follow-up (day 250) | Truong et al. [37] |
Table 3. Cont.

| Age/Sex (Identifier) | Condition                                                                 | CCP Schedule (and Titer) | Co-Treatments | SARS-CoV-2 Strain          | Spike Mutations                                                                 | First Detected at Day | Outcome                  | Ref                |
|----------------------|---------------------------------------------------------------------------|--------------------------|---------------|----------------------------|---------------------------------------------------------------------------------|-----------------------|------------------------|-------------------|
| 50/M                 | kidney transplant recipient (tacrolimus, steroids)                        | 1                        | tocilizumab    | B.1.369                    | Q493R, ΔAL243–244 had ~70% frequency; ALGVY141–144, E484K and Q493K had ~30%, ~20% and ~10% frequency | 21                    | died on day 94          | Chen et al. [38]    |
| 75/M                 | B-CLL (FCR, ibrutinib)                                                   | 2 units on day 70, 2 units on days 127–129 | remdesivir days 24–33 and 60–64 | n.a.                      | H49Y, ΔY144, ΔAL243–244, ΔL421H, A243E, F498S, N1178N, and C1250F              | 80                    | still positive at end of follow-up (day 335) | Monrad et al. [39] |
| 60/M                 | mantle cell lymphoma and associated B-cell immunodeficiency (rituximab, bispecific mAb, cyclophosphamide, doxorubicin, prednisone) | 31, 122                  | remdesivir days 30 and 122 | n.a.                      | mutations in ORF1a but not in spike                                            | n.a.                  | still positive at end of follow-up (day 156) | Baang et al. [40] |
| 40/F                 | diffuse large B-cell lymphoma (chimeric antigen receptor T lymphocytes) and hypogammaglobulinemia | high-titer day 2, 313 | IVIG, remdesivir days 2 and 313 | B.1.332                    | ΔLHR244–246 and A243G                                                        | 313 poor causation    | discharged day 32, cleared at day 335 | Nuessenblatt et al. [41] |
| 70/F (A)             | follicular lymphoma (obinutuzumab-CHRP)                                    | 23, 34, 39, 55, 56, 62, 65, 70, 73, 77, 84, 96, 90, 94, 106 | steroids       | B.1.1.29                    | L18F, R66Q, ΑY144                                                           | 50                    | died 5 months later    | Khatamzas et al. [42] |
| 70/M                 | mantle cell lymphoma (R-BAC)                                              | 88                       | n.a.          | B.1.1                       | H69Y/P, V70G and S982A                                                       | 238                   | died on day 271, still positive at day 268 | Sepulcri et al. [43] |
| 40/M                 | autologous hematopoietic stem cell transplant due to a diffuse large B-cell lymphoma | 2 doses on days?         | IVIg           | B.1.1.128                   | ΔLGV141–143 → ΔLGVY141–144                                                  | 134                   | negative PCR on day 196 | Mendes-Correa et al. [44] |

Table 4 summarizes the data from reports of within-host clonal evolution within immunocompromised patients not treated with nAb-based therapeutics.

Table 4. Intrahost variation in spike sequence detected in immunocompromised patients not receiving nAb-based treatments.

| Age/Sex (Identifier) | Condition                                                                 | Antiviral Treatments | SARS-CoV-2 Strain | Spike Mutations | First Detected at Day | Outcome | Ref |
|----------------------|---------------------------------------------------------------------------|---------------------|-------------------|-----------------|-----------------------|---------|-----|
| 47/F                 | diffuse large B-cell lymphoma (rituximab plus polychemotherapy)          | n.a.                | B.1.1.163         | Y453F, ΔHV69–70, S50L, ΔALGVY141–144, T470N, and D737V | 120      | negative PCR on day 132 | Bazylkin et al. [7] |
| 61/F                 | diffuse large B-cell lymphoma stage IVB                                   | remdesivir for 10 days, high-dose steroids for 7 days | B.1.1.401 | V3G, S50L, N87S, A222V, ΔLTTTRQLPAPTYN18–30 and ΔALGVY141–144 | 164      | negative PCR at day 197 | Borges et al. [45] |
| 3/F (I)              | B-cell acute lymphoblastic leukemia (chemotherapy)                        | n.a.                | 20C               | silent 110F (22792:C/A) | 27                   | negative PCR at day 91 | Truong et al. [37] |
| 2/M (3)              | B-cell acute lymphoblastic leukemia                                       | remdesivir for 5 days | 20C               | 20C             | 139                  | negative PCR at day 196 |                   |
| 37/F                 | advanced HIV and antiretroviral treatment failure                         | dexamethasone       | B.1.1.273         | E484K           | 6                    |                     | Karim et al. [46] |
|                      |                                                                           |                      |                   | K417T and F490S  | 71                   | negative at day 233  |                   |
|                      |                                                                           |                      |                   | L455F and F466L  | 106                  |                     |                   |
|                      |                                                                           |                      |                   | D472Y and N501Y  | 190                  |                     |                   |
Table 4. Cont.

| Age/Sex (Identifier) | Condition | Antiviral Treatments | SARS-CoV-2 Strain | Spike Mutations | First Detected at Day | Outcome | Ref |
|----------------------|-----------|----------------------|-------------------|-----------------|-----------------------|---------|-----|
| 80/M | chronic lymphocytic leukemia and hypogammaglobulinemic | remdesivir days 213–230, REGN-COV-2 day 265 | B.52 | L179 | 58 | negative PCR day 311 | Kavanagh Williamson et al. [47] |
| 40/M | autologous hematopoietic stem cell transplant due to a diffuse large B-cell lymphoma | IVIg | B.1.128 | ALGV141–143 → ALGV141–144 | negative PCR on day 196 | Mendes-Correa et al. [44] |
| n.a./n.a. | transplant recipient | remdesivir | n.a. | S13I, T95I, E484G, F490L, ∆LGVY141–144, ∆LHG524–247, and ∆SPPRARS680–687 | n.a. | n.a. | Weigang et al. [48] |
| n.a./n.a. | 18 B-cell non-Hodgkin lymphoma | 44% CCP 37% remdesivir | n.a. | n.a. | requested | n.a. | Lee et al. [49] |

Figure 2 depicts the spike RBD mutations of concern for mAb binding detected in vitro and in vivo and the spike mutations detected after CCP usage.

Figure 2. (Top panel) The full SARS-CoV-2 S (spike) glycoprotein homotrimer (PDBID 6VXX) [16] in the prefusion conformation is shown in surface representation, with each spike monomer colored a different shade of green. N-linked glycosylations which were resolved in the cryo-EM map in this structure (16/22 sequons per protomer) are displayed as magenta sticks. The receptor binding domains (RBDs), in the closed state, are highlighted in 3 shades of blue corresponding to the shade of the corresponding trimer.
Escape mutations from case reports of patients treated with CCP are highlighted in orange. Spike mutations associated with immune escape from clinically approved mAb treatments in vitro or from case reports are highlighted in red, while escape mutations identified in both patients who received clinically approved mAb treatments and CCP treatment are colored yellow. The full spike is shown oriented along the long axis (left) and rotated 90 degrees to display mutations concentrated in the RBDs. Note that mutations located on unresolved loops on the cryo-EM map of the full spike are not visualized (L18, V70, Y144, Y145, D146, R246, W258, G446, N460, I472, V483, E484, G485, F486, R682, N1178 and C1250). (Bottom panel) A table summarizing escape mutations localized to the RBD resulting from mAb treatments in vitro and case reports, as well as from CCP treatment. The crystal structure of single RBD domain (PBDID: 7BWJ) [17] from a more complete model (no missing loops) is displayed in surface view with the secondary structure superimposed in cartoon representation. Each escape mutation residue is highlighted by coloration according to the legend to right, and sidechains shown as sticks. In cases where a certain position corresponds to escape mutations from multiple treatments, the position is colored white and the label includes asterisks with the colors corresponding to each treatment where the escape mutation was identified. All figures were generated in PyMOL [18].

4. Discussion

Escape from nAb-based therapeutics provides a crucial demonstration that these immune therapies target protective antigens, which the pathogen actively evades. Hence, the emergence of neutralizing-resistant variants in individuals receiving mAb and CCP provides powerful evidence for their antiviral activity. This evidence is independent of reduction in viral load, which has been reported with mAbs given early in disease but have been an inconsistent finding in randomized controlled trials (RCT) of CCP for COVID-19 [50].

Obtaining the frequencies for this phenomenon from case series is not possible due to the high risk of selection biases, which would yield unrealistically high frequencies. In contrast, RCTs with their control groups are the suggested reference. With bamlanivimab, resistance was reported in 7% of patients, regardless of dosage (700/2800/7000 mg) versus <1% in patients treated with placebo [22,29]. Apart from registration trials, the largest case series to date evaluated the impact of mAbs on the nasopharyngeal (NP) viral load and virus quasi-species of mAb-treated patients using single-molecule real-time sequencing after bamlanivimab alone (4 patients), bamlanivimab/etesevimab (23 patients) and casirivimab/Imdevimab (5 patients) [32]. To date a single case of immune escape has been reported for the non-overlapping REGN-COV2 cocktail, and accordingly hamster models and clinical trials showed no emergence of variants [51]. Since mAb therapy by definition targets only a single epitope within the RBD, it is unsurprising that escape mutations observed after in vitro and in vivo selection by these mAbs were single amino acid substitutions localized almost exclusively to the RBD (Figure 2, bottom panel; Tables 1 and 2), as expected from in vitro studies with single mAb, but largely prevented by non-overlapping mAb cocktails [52].

In contrast to mAb therapeutics, immune escape under CCP has not been investigated in RCTs. Hence, evidence exclusively stems from case series and case reports [53] and is further complicated by exposure to multiple CCP units from different donors, each one having a polyclonal response at differing titers and affinity. Unfortunately, nAb titers were very rarely determined or reported, precluding correlation between the emergence of resistance and subneutralizing CCP doses. Overall, it seems that escape variants from CCP selection have not been reported as commonly nor emerged as fast, e.g., none of the eight recipients of hematopoietic stem cell transplantation or chimeric antigen receptor T (CART) lymphocytes who were treated with CCP and tested SARS-CoV-2-positive for 2 months showed significant mutations compared to the original strain [54]. A review of the spike protein changes associated with resistance after CCP therapy reveals that most of them had in-frame amino acid deletions in a flexible region that is partially solvent exposed and forms a β strand: plasticity may contribute to the structural permissibility of the identified deletions. The NTD is a flexible region that can be affected by immune escape via either
insertions (causing additional glycosylation sites [12]) or recurrently deleted regions (RDR) ∆HV69–70 (RDR1), ∆LGYY141–144 and ∆D146 (RDR2), ∆I210 (RDR3) and ∆L243–244 (RDR4) [55]: RDR1, RDR2 and RDR4 correspond to NTD loops N2, N3 and N5, whereas RDR3 falls between N4 and N5.

Deletions of amino acids from a protein structure generally result in greater structural changes than single amino acid changes, since these reduce the size of the protein and can trigger changes that propagate through the whole structure. Furthermore, the mechanism for the emergence of deletion variants appears to be very different from the single amino acid changes that are frequent from error-prone RNA replication and could involve deletions from RNA editing. Since CCP targets a large number of epitopes in the spike protein while mAbs target a single epitope, these molecular differences parallel what is expected from their respective selection pressures in the sense that escape from polyclonal preparations requires larger antigenic structural changes than escape from mAbs. In contrast to escape mutations selected for by mAb therapy, CCP selection yields point mutations throughout the spike protein. This reflects the vast antigenic surface area covered by the polyclonal antibodies within CCP. Escape mutations would be theoretically selected for on the basis of the most potent antibodies present in a particular CCP unit, which may vary markedly from donor to donor, which could explain the generally divergent evolution of SARS-CoV-2 in the presence of CCP. However, residues 141–144 and 243–244 are the sites of mutations or deletions in several cases, indicating these sites may offer effective escape from CCP derived from many donors, possibly by triggering a large-scale conformational rearrangement, as discussed above. As RBD binding antibodies are often neutralizing via ACE2 receptor occlusion, it is interesting that only 23% of CCP case studies identified the escape mutations within the RBD (Figure 2, top panel; Table 3). This suggests that antibody binding to other sites on the spike protein may have additional mechanisms of neutralization (i.e., by preventing conformational change after ACE2 engagement), or that additional antibody mediated immune responses (e.g., ADCC) are equally important as direct neutralization to the antiviral response to SARS-CoV-2.

Nothing can be inferred about the fitness of an emerging mutant in the absence of selective pressure, but it is of interest that one variant with the E484K mutant that emerged after bamlanivimab therapy was able to infect multiple household contacts [27]. In vitro, several mutants showed similar infectivity to the wild-type strain but resistance to different CCP donors [36]. In one instance of immune escape associated with CCP, a variant with D796H mutation manifested modestly reduced sensitivity to neutralization by CCP that was associated with reduced infectivity, which was only partly compensated by ∆HV69–70 [36]. Even if immune escape in registration trials has been a rare phenomenon, it should be considered that in real-world practice, mAbs targeting of the SARS-CoV-2 spike protein is being reserved for use in high-risk (immunocompromised) patients. Considering the huge size of the pandemic, the likelihood of immune escape becomes relevant, raising the possibility that rare variants with enhanced fitness could drive the next pandemic waves. Notably, several mutations have recurred in VOC and VOIs (e.g., E484K found in Beta and Gamma, E484Q found in Delta, or ∆LHR244–246 [41] found in VOI lambda), raising the possibility that such variants emerged during the treatment of patients (iatrogenic variants), but such inference will likely remain very hard to prove. E406W mutation, which causes resistance to REGN-COV-2, has never been reported in GISAID, and other E406 mutations remain exceedingly rare (worldwide, 318 cases of E406Q, 41 cases of E406D, and 2 cases each from USA for E406G, E406A, E406K, and 1 case of E406V out of 4,410,787 sequences deposited in GISAID as of 13 December 2021). The same is true for sotrovimab resistance, with E340 and P337 mutations exceedingly rare to date (E340K in 244 sequences and P337T in 90) (source: Outbreak.info). Similarly, Q493R, which causes resistance to bamlanivimab + etesevimab, had only been reported in 244 sequences and Q493K in 138 sequences, before becoming one of the hallmark mutations of VOC Omicron. L452R, which causes resistance to regdanvimab, also became prevalent first in VOI Epsilon and
then in VOC Delta (source: Outbreak.info). Lack of fixation of those mutations facilitates the imputation that these require mAb selective pressure and/or effective infection control techniques in the care of those patients to prevent spill over to the general population.

Within-host variation (so-called “quasi-species swarm”) is a natural phenomenon which has been reported for SARS-CoV-2 in immunocompetent patients and ultimately facilitates the persistence of infection. Among 33 patients having positive NPS PCR for an average of 18 days, Voloch et al., observed a distinguishing pattern of mutations over the course of the infection mainly driven by increasing A→U and decreasing G→A signatures, including spike mutations (V362L, T553I, H655Y, A688V, S691F, S884F, V1176F). G→A mutations are driven by the RNA-editing enzyme activities typical of innate immunity [56]. Nevertheless, several covariates can facilitate immune escape.

Immunosuppression has been postulated to be an accelerator for viral evolution. Actually, Table 4 shows that very few case reports have detailed intraclonal (within-host) evolution in patients receiving immunosuppressive treatment, and, in the absence of nAb-based therapeutics, spike mutations rarely occurred [54].

On the other hand, co-administered small chemical antivirals can be mutagenic per se. Remdesivir has both amino and imino tautomers when pairing with RNA bases [57]. Both amino-remdesivir:G and imino-remdesivir:C pairs are mutagenic. It has hence been proposed than nAb-based therapeutics could amplify the mutations induced by remdesivir [3]. In this regard, Table 4 shows that many of the mAb- or CCP-associated mutations emerged in individuals who were or had been treated with remdesivir (but neither mAbs nor CCP), consistent with the notion that antiviral therapy could potentiate the emergence of antibody-resistant mutations.

5. Conclusions

In summary, our survey of the available mutational data show that escape variants associated with mAb and CCP therapy manifest different type of mutations. For mAbs, most mutations are single amino acid replacements in the RBD domain, while most variants elicited in patients treated with CCP exhibited amino acid deletions. In fact, it is noteworthy that RBD mutations were relatively rare in CCP escape variants. Although the numbers are relatively small, which suggests caution in making generalizations, this dichotomy in geography of mAb and CCP mutations could reflect the fact that mAbs target a single epitope where the mAb–antigen interaction can be significantly altered by single amino acid changes while CCP targets many epitopes and has several mechanisms of action, such that evading polyclonal antibody immunity is likely to require much larger spike protein structural changes. Despite the relatively small set of variants for which there is molecular data available, the large variation of molecular solutions that allow SARS-CoV-2 to escape antibody-mediated protection is striking and suggest the need for continued vigilance in genomic surveillance, especially in cases refractory to therapy.

Author Contributions: D.F. conceived the manuscript; F.M. analyzed the literature; S.M. provided Figure 2 and revised the final version; A.C. revised the final version, M.F. provided Figure 1 and revised the final version. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Data Availability Statement: The data presented in this study are openly available in PubMed, medRxiv and bioRxiv.

Conflicts of Interest: We declare we do not have any conflict of interest related to this manuscript.

Abbreviations

nAb neutralizing antibodies;
CCP COVID-19-convalescent plasma;
PSM propensity score-matched
RCT randomized controlled trials
References

1. Egeren, D.V.; Novokhodko, A.; Stoddard, M.; Tran, U.; Zetter, B.; Rogers, M.; Pentelute, B.L.; Carlson, J.M.; Hixon, M.S.; Joseph-McCarthy, D.; et al. Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein. medRxiv 2020. [CrossRef]

2. Landis, J.; Moorad, R.; Pluta, L.J.; Caro-Vegas, C.; McNamara, R.P.; Eason, A.B.; Bailey, A.; Villamor, F.C.S.; Juarez, A.; Wong, J.P.; et al. Intra-host evolution provides for continuous emergence of SARS-CoV-2 variants. medRxiv 2021. [CrossRef]

3. Colson, P.; Devaux, C.A.; Lagier, J.C.; Gautret, P.; Raoult, D. A Possible Role of Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 Variants. J. Clin. Med. 2021, 10, 3276. [CrossRef] [PubMed]

4. Kabinger, F.; Stiller, C.; Schmitzová, J.; Dienemann, C.; Hillen, H.S.; Höbartner, C.; Cramer, P. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 2021, 28, 740–746. [CrossRef]

5. Starr, T.N.; Greaney, A.J.; Hilton, S.K.; Ellis, D.; Crawford, K.H.D.; Dingens, A.S.; Navarro, M.J.; Bowen, J.E.; Tortorici, M.A.; et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host Microbe 2021, 29, 44–57.e9. [CrossRef] [PubMed]

6. Greaney, A.J.; Starr, T.N.; Gilchuk, P.; Zost, S.J.; Binshtein, E.; Loes, A.N.; Hilton, S.K.; Huddleston, J.; Eguia, R.; Crawford, K.H.D.; et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host Microbe 2021, 29, 44–57.e9. [CrossRef] [PubMed]

7. Bazykin, G.; Stanievich, O.; Danilenko, D.; Fadeev, A.; Komissarova, K.; Ivanova, A.; Sergeeva, M.; Safina, K.; Nabieva, E.; Klink, G.; et al. Emergence of Y453F and Δ69-70HV Mutations in a Lymphoma Patient with Long-Term COVID-19. Available online: https://viriologen.org/it/-emergence-of-y453f-and-69-70hv-mutations-in-a-lymphoma-patient-with-long-term-covid-19-580 (accessed on 14 December 2021).

8. Javanmardi, K.; Chou, C.-W.; Terrace, C.; Annapareddy, A.; Kaoud, T.S.; Guo, Q.; Lutgens, J.; Zorkic, H.; Horton, A.P.; Gardner, E.C.; et al. Rapid characterization of spike variant spikes via mammalian cell surface display. bioRxiv 2021. [CrossRef] [PubMed]

9. Starr, T.N.; Greaney, A.J.; Addetia, A.; Hannon, W.W.; Choudhary, M.C.; Dingens, A.S.; Li, J.Z.; Bloom, J.D. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science 2021, 371, 850–854. [CrossRef]

10. Starr, T.N.; Greaney, A.J.; Dingens, A.S.; Bloom, J.D. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep. Med. 2021, 20, 2. [CrossRef]

11. Garrett, M.E.; Galloway, J.; Chu, H.Y.; Ittel, H.L.; Stoddard, C.I.; Wolf, C.R.; Logue, J.K.; McDonald, D.; Matsen, F.A.; Overbaugh, J. High resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies. bioRxiv 2020. [CrossRef] [PubMed]

12. Andreano, E.; Piccini, G.; Lacastro, D.; Casalino, L.; Johnson, N.V.; Paciello, I.; Dal Monego, S.; Pantano, E.; Manganaro, N.; Manenti, A.; et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. Proc. Natl. Acad. Sci. USA 2021, 118, e210315118. [CrossRef] [PubMed]

13. Wang, Z.; Schmidt, F.; Weisblum, Y.; Muecksch, F.; Barnes, C.O.; Finkin, S.; Schaefer-Babajew, D.; Cipolla, M.; Gaebler, C.; Lieberman, J.A.; et al. mRNA Vaccine-Elicited Antibodies to SARS-CoV-2 and Circulating Variants. Available online: https://www.biorxiv.org/content/biorxiv/early/2021/01/19/2021.01.15.426911.full.pdf (accessed on 14 December 2021).

14. Casadevall, A.; Henderson, J.; Joyner, M.; Pirofski, L.-A. SARS-CoV-2 variants and convalescent plasma: Reality, fallacies, and opportunities. J. Clin. Investig. 2021, 131, e148832. [CrossRef] [PubMed]

15. Valesano, A.L.; Rumfelt, K.E.; Dimcheff, D.E.; Blair, C.N.; Fitzsimmons, W.J.; Petrie, J.G.; Martin, E.T.; Lauring, A.S. Temporal dynamics of SARS-CoV-2 mutation accumulation within and across infected hosts. PLoS Pathog. 2021, 17, e1009499. [CrossRef] [PubMed]

16. Walls, A.C.; Park, Y.J.; Tortorici, M.A.; Wall, A.; McGuire, A.T.; Veesler, D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020, 181, 281–292.e6. [CrossRef] [PubMed]

17. Ju, B.; Zhang, Q.; Ge, J.; Wang, R.; Sun, J.; Ge, X.; Yu, J.; Shan, S.; Zhou, B.; Song, S.; et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 2020, 584, 115–119. [CrossRef] [PubMed]

18. The PyMOL Molecular Graphics System, Version 2.4.1. Schrödinger, LLC. Available online: https://pymol.org/2/ (accessed on 21 December 2021).

19. Wang, P.; Nair, M.S.; Li, R.; Iketani, S.; Luo, Y.; Guo, Y.; Wang, M.; Yu, J.; Zhang, B.; Kwong, P.D.; et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 2021, 593, 130–135. [CrossRef]

20. Choi, B.; Choudhary, M.C.; Regan, J.; Sparks, J.A.; Padera, R.F.; Qiu, X.; Solomon, I.H.; Kuo, H.-H.; Boucau, J.; Bowman, K.; et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N. Engl. J. Med. 2020, 383, 2291–2293. [CrossRef] [PubMed]

21. Clark, S.A.; Clark, L.E.; Pan, J.; Liese, A.; McKay, L.G.A.; Shankar, S.; Johnson, R.I.; Brusic, V.; Choudhary, M.C.; Regan, J.; et al. SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. Cell 2021, 184, 2605–2617.e18. [CrossRef] [PubMed]

22. Choudhary, M.C.; Chew, K.W.; Deo, R.; Flynn, J.P.; Regan, J.; Crain, C.R.; Moser, C.; Hughes, M.; Ritz, J.; Ribeiro, R.M.; et al. Persistence and Evolution of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy. medRxiv 2021. [CrossRef]

23. Truffot, A.; Andreani, J.; Le Marechal, M.; Caporossi, A.; Epaulard, O.; Poignard, P.; Sylvie, L. SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monoclonal. Emerg. Infect. Dis. 2021, 27, 2725–2728. [CrossRef] [PubMed]

24. Lohr, B.; Niemann, D.; Verheyen, J. Bamlanivimab treatment leads to rapid selection of immune escape variant carrying E484K mutation in a B.1.1.7 infected and immunosuppressed patient. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2021, 73, 2144–2145. [CrossRef] [PubMed]
46. Karim, F.; Moosa, M.Y.; Gosnell, B.; Sandile, C.; Giandhari, J.; Pillay, S.; Tegally, H.; Wilkinson, E.; San, E.J.; Msomi, N.; et al. Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infection. medRxiv 2021. [CrossRef]

47. Kavanagh Williamson, M.; Hamilton, F.; Hutchings, S.; Pymont, H.M.; Hackett, M.; Arnold, D.; Maskell, N.; MacGowan, A.P.; Albur, m.; Jenkins, M.; et al. Chronic SARS-CoV-2 infection and viral evolution in a hypogammaglobulinaemic individual. medRxiv 2021. [CrossRef]

48. Weigang, S.; Fuchs, J.; Zimmer, G.; Schnepf, D.; Kern, L.; Beer, J.; Luxenburger, H.; Ankerhold, J.; Falcone, V.; Kemming, J.; et al. Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient: A source of immune escape variants. medRxiv 2021. [CrossRef] [PubMed]

49. Lee, C.Y.; Shah, M.K.; Hoyos, D.; Solovyov, A.; Douglas, M.; Taur, Y.; Maslak, P.G.; Babady, N.E.; Greenbaum, B.; Kamboj, M.; et al. Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies. medRxiv 2021. [CrossRef] [PubMed]

50. Weigang, S.; Fuchs, J.; Zimmer, G.; Schnepf, D.; Kern, L.; Beer, J.; Luxenburger, H.; Ankerhold, J.; Falcone, V.; Kemming, J.; et al. Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient: A source of immune escape variants. medRxiv 2021. [CrossRef] [PubMed]

51. Copin, R.; Baum, A.; Wloga, E.; Pascal, K.E.; Giordano, S.; Fulton, B.O.; Zhou, A.; Negron, N.; Lanza, K.; Chan, N.; et al. REGEN-COV protects against viral escape in preclinical and human studies. bioRxiv 2021, preprint. [CrossRef]

52. Baum, A.; Fulton, B.O.; Wloga, E.; Copin, R.; Pascal, K.E.; Russo, V.; Giordano, S.; Lanza, K.; Negron, N.; Ni, M.; et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 2020, 369, 1014–1018. [CrossRef]

53. Harvey, W.T.; Carabelli, A.M.; Jackson, B.; Gupta, R.K.; Thomson, E.C.; Harrison, E.M.; Ludden, C.; Reeve, R.; Rambaut, A.; Peacock, S.J.; et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 2021, 19, 409–424. [CrossRef] [PubMed]

54. Aydillo, T.; Gonzalez-Reiche, A.S.; Aslam, S.; van de Guchte, A.; Khan, Z.; Obla, A.; Dutta, J.; van Bakel, H.; Aberg, J.; Garcia-Sastre, A.; et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N. Engl. J. Med. 2020, 383, 2586–2588. [CrossRef]

55. McCarthy, K.R.; Rennick, L.J.; Nambulli, S.; Robinson-McCarthy, L.R.; Bain, W.G.; Haidar, G.; Duprex, W.P. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. Science 2021, 371, 1139–1142. [CrossRef] [PubMed]

56. Voloch, C.M.; da Silva Francisco, R., Jr.; de Almeida, L.G.P.; Brustolini, O.J.; Cardoso, C.C.; Gerber, A.L.; Guimarães, A.P.d.C.; Leitão, I.d.C.; Mariani, D.; Ota, V.A.; et al. Intra-host evolution during SARS-CoV-2 prolonged infection. Virus Evol. 2021, 7, veaab078. [CrossRef] [PubMed]

57. Singh, V.; Fedele, B.I.; Essigmann, J.M. Role of tautomerism in RNA biochemistry. RNA 2015, 21, 1–13. [CrossRef] [PubMed]